Pharmathen Competitors and Similar CompaniesClear all

Pharmathen's competitors and similar companies include Joincare, Sanofi Pasteur, Mundipharma and Shenzhen Salubris Pharmaceutical.

	Pharmathen Pharmathen is a pharmaceutical company engaged in the research, development, and distribution of drugs.	Joincare Joincare (健康元药业集团股份有限公司) is a company that manufactures and supplies pharmaceuticals products.	Sanofi Pasteur Sanofi Pasteur is a pharmaceutical company that develops, manufactures, and supplies vaccines.	Mundipharma Mundipharma is a global network of independent associated companies focused on the development of medicines.	Shenzhen Salubris Pharmaceutical Shenzhen Salubris Pharmaceutical (深圳信立泰药业股份有限公司) is a pharmaceutical company that develops and supplies drugs.
Founding Date	Founding Date 1969	Founding Date 1992	Founding Date 1989	Founding Date 1952	Founding Date 1998
Type	Type Private	Type Public	Type Subsidiary	Type Private	Type Public
Tags	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma
Locations	Locations Amstelveen, NL HQ Marousi, GR Amman, JO St Albans, GB	Locations Shen Zhen, CN HQ	Locations Lyon, FR HQ	Locations Cambridge, GB HQ Wien, AT Mechelen, BE Sofia, BG Markham, CA Dali, CY see more	Locations Shenzhen, CN HQ
Employees	Employees 1,063	Employees 14,350	Employees 6,7454% increase	Employees 2,112	Employees 3,596
Valuation ($)	Valuation ($) N/A	Valuation ($) 3 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 5 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥14.9b (FY, 2025)	Revenue (est.) €2.8b (FY, 2021)	Revenue (est.) N/A	Revenue (est.) ¥4.2b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods ¥5.7b (FY, 2025)	Cost of goods €505m (FY, 2021)	Cost of goods N/A	Cost of goods ¥1.1b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit ¥9.3b (FY, 2025)	Gross profit €2.3b (FY, 2021)	Gross profit N/A	Gross profit ¥3.2b (FY, 2025)
Net income	Net income N/A	Net income ¥2.9b (FY, 2025)	Net income €605m (FY, 2021)	Net income N/A	Net income ¥652.8m (FY, 2025)